This company has been acquired
MYOV Stock Overview
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Myovant Sciences Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$26.98 |
| 52 Week High | US$27.06 |
| 52 Week Low | US$7.67 |
| Beta | 2.15 |
| 1 Month Change | 0.26% |
| 3 Month Change | 0.41% |
| 1 Year Change | 125.40% |
| 3 Year Change | 278.93% |
| 5 Year Change | 44.51% |
| Change since IPO | 103.47% |
Recent News & Updates
Myovant Sciences GAAP EPS of -$0.56 beats by $0.08, revenue of $100.23M misses by $2.13M
Jan 26Not The Buyout Offer That Myovant Shareholders Hoped For
Oct 25Recent updates
Myovant Sciences GAAP EPS of -$0.56 beats by $0.08, revenue of $100.23M misses by $2.13M
Jan 26Not The Buyout Offer That Myovant Shareholders Hoped For
Oct 25Myovant Sciences rejects Sumitovant Biopharma's $22.75/share takeover offer
Oct 03Women Can Thank Pfizer And Myovant For MYFEMBREE
Sep 20Myovant Sciences: Regulatory Overhang Cleared
Aug 29Myovant Sciences upgraded to outperform at SVB following additional Myfembree indication
Aug 09Myovant stock gains ~6% after hours on Q1 revenue jump
Jul 27Myovant Makes Commercial Progress As It Waits For FDA Decision On Myfembree
Jul 18Analyst Forecasts For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher
Apr 28
Myovant: Poised To Overcome Regulatory Issues
Apr 26Regulatory Setback Brings Myovant Sciences Stock To Attractive Levels
Apr 13Myovant: Approved Drugs And Upcoming Catalysts Make This A Great Long-Term Play
Mar 26Myovant: Catalysts Powering More Upside
Jan 02Myovant Sciences: Becoming A Blockbuster
Jun 02Myovant Sciences rises on FDA approval for relugolix
May 26Analysts Just Shipped A Substantial Upgrade To Their Myovant Sciences Ltd. (NYSE:MYOV) Estimates
May 14Why The Misunderstood Pfizer Deal Makes Myovant A Great Low-Risk Investment
May 09New Forecasts: Here's What Analysts Think The Future Holds For Myovant Sciences Ltd. (NYSE:MYOV)
Feb 17Earnings Update: Myovant Sciences Ltd. (NYSE:MYOV) Just Reported And Analysts Are Boosting Their Estimates
Feb 13Analysts' Revenue Estimates For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher
Jan 12Myovant cut to neutral at Goldman Sachs on ‘lack of driving catalysts’
Jan 06Myovant Sciences announces distribution of ORGOVYX in the U.S.
Jan 05Myovant Sciences gains 22% on relugolix deal with Pfizer
Dec 28Have Insiders Been Selling Myovant Sciences Ltd. (NYSE:MYOV) Shares This Year?
Dec 23
Myovant Sciences’ FDA win leads to Bullish views at Baird
Dec 21Myovant Sciences scores FDA approval for Orgovyx in prostate cancer
Dec 18Myovant Sciences (NYSE:MYOV) Shareholders Have Enjoyed A 60% Share Price Gain
Nov 18Myovant Sciences: More Than Meets The Eye
Nov 12The Sell-Off In Myovant Is Unjustified By Fundamentals
Nov 09Shareholder Returns
| MYOV | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.1% | 1.5% | 1.2% |
| 1Y | 125.4% | 1.1% | 24.7% |
Return vs Industry: MYOV exceeded the US Biotechs industry which returned 2.8% over the past year.
Return vs Market: MYOV exceeded the US Market which returned -9.9% over the past year.
Price Volatility
| MYOV volatility | |
|---|---|
| MYOV Average Weekly Movement | 0.3% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MYOV has not had significant price volatility in the past 3 months.
Volatility Over Time: MYOV's weekly volatility has decreased from 11% to 0% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 579 | Dave Marek | myovant.com |
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company’s lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction.
Myovant Sciences Ltd. Fundamentals Summary
| MYOV fundamental statistics | |
|---|---|
| Market cap | US$2.62b |
| Earnings (TTM) | -US$183.77m |
| Revenue (TTM) | US$379.11m |
6.9x
P/S Ratio-14.3x
P/E RatioIs MYOV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MYOV income statement (TTM) | |
|---|---|
| Revenue | US$379.11m |
| Cost of Revenue | US$209.66m |
| Gross Profit | US$169.45m |
| Other Expenses | US$353.22m |
| Earnings | -US$183.77m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.89 |
| Gross Margin | 44.70% |
| Net Profit Margin | -48.47% |
| Debt/Equity Ratio | -64.3% |
How did MYOV perform over the long term?
See historical performance and comparison